A nurse practitioner discusses ASCO’s recommendations of CDK4/6 inhibitors—namely abemaciclib and ribociclib—in certain high-risk breast cancer settings.
Get detailed information on Abemaciclib, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...
On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be ...
On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback